Global Antiretroviral Therapy Market Overview:
Anti-retroviral therapies are used to treat infections caused by retroviruses, most often HIV. A retrovirus is a type of virus that belongs to the Retroviridae family and carries its genetic blueprint in the form of ribonucleic acid (RNA). Anti-retroviral medications work by preventing these viruses from multiplying rather than killing them. Growing cases of sexually transmitted diseases drive the antiretroviral therapy market.
- Rising Burden of HIV
- Growing Cases of Sexually Transmitted Diseases
- Easy Availability of Diagnosis Tests Treatments
- Patient’s Awareness regarding Diseases and Treatment in Developing Countries
- Stringent FDA Guidelines for Approval and Commercialization of New Drugs
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Gilead Sciences, Inc. (United States), F. Hoffmann-La Roche (Switzerland), ViiV Healthcare (United States), Boehringer Ingelheim (Germany), Janssen Pharmaceuticals (Belgium), Mylan (United States), Abbvie (United States), Bionor Pharma (Norway) and Vertex Pharmaceuticals (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Antiretroviral Therapy market by 2026. Considering Market by Route of Administration, the sub-segment i.e. Oral will boost the Antiretroviral Therapy market. Considering Market by Class, the sub-segment i.e. Nucleoside Reverse Transcriptase Inhibitors will boost the Antiretroviral Therapy market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Antiretroviral Therapy market.
Latest Market Insights:
On Apr 29, 2021, ImmunityBio, Inc. announced that the U.S. Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research has launched a Phase 2 clinical trial in Thailand to evaluate ImmunityBio’s interleukin-15 (IL-15) superagonist Anktiva® (also called N-803) administered in combination with antiretroviral therapy (ART) during acute HIV infection as an experimental therapy to target and inhibit early establishment of HIV ‘reservoirs’ in infected individuals.
On July 02, 2020, U.S. Food and Drug Administration approved Rukobia (fostemsavir), a new type of antiretroviral medication for adults living with HIV who have tried multiple HIV medications and whose HIV infection cannot be successfully treated with other therapies because of resistance, intolerance or safety considerations.
What Can be Explored with the Antiretroviral Therapy Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Antiretroviral Therapy Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Antiretroviral Therapy
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Antiretroviral Therapy market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Antiretroviral Therapy market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants and Investors, Antiretroviral Therapy Provider, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Frequently Asked Questions (FAQ):1. What is the growth rate predicted for the Global Antiretroviral Therapy Market?
The Antiretroviral Therapy market is expected to see a CAGR of % during projected year 2020 to 2026.
2. Who are the top performing companies in Antiretroviral Therapy Market?
Top performing companies in the Global Antiretroviral Therapy market are Gilead Sciences, Inc. (United States), F. Hoffmann-La Roche (Switzerland), ViiV Healthcare (United States), Boehringer Ingelheim (Germany), Janssen Pharmaceuticals (Belgium), Mylan (United States), Abbvie (United States), Bionor Pharma (Norway) and Vertex Pharmaceuticals (United States), to name a few.
3. What trending factors would impact Antiretroviral Therapy Market growth most?
"Increasing Investment in R&D" is seen as one of major influencing trends for Antiretroviral Therapy Market during projected period 2020-2026.